RxDoctor Payments Data

Patrick Cogley, MD

Family Medicine · Grinnell, IANPI 1417941717

Payments from drug & device makers

$1,404in general payments, 2019–2025

Across 99 payments — averaging $14.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$473
  • Phathom Pharmaceuticals, Inc.$164
  • Lilly USA, LLC$146
  • Novo Nordisk$126
  • AstraZeneca$101
  • Boehringer Ingelheim$88
  • plus $307 from 10 others

What the payments were for

  • Food & beverage$1,404100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,404 in reported general payments places this provider in the 85th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$55,545
Medicare patients
297
Services billed
1,258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide12$12,361
EliquisApixaban19$12,202
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$12,028
JanuviaSitagliptin Phosphate12$6,762
Tamsulosin Hcl30$786
Potassium Chloride15$704
Isosorbide Dinitrate13$656
Albuterol Sulfate HfaAlbuterol Sulfate27$635
Atorvastatin Calcium77$632
Carbidopa-LevodopaCarbidopa/Levodopa16$533
Pravastatin Sodium29$381
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen24$368
Metoprolol Succinate41$368
Omeprazole22$357
Sucralfate18$297

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus$126$12,36112 claims
PfizerEliquis$473$12,20219 claims
GSKTrelegy Ellipta$15$12,02812 claims
MerckJanuvia$37$6,76212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Grinnell

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →